Monday 24 / August / 2026
Indian scientists have developed a promising “smart” cancer drug candidate designed to become active mainly inside cancer cells, potentially offering a more targeted approach than conventional chemotherapy.
The research was led by Dr Asis Bala of the Institute of Advanced Study in Science and Technology (IASST), an autonomous institute under India’s Department of Science and Technology, in collaboration with Dr K.P. Bhabak of IIT Guwahati.
The drug candidate, named RK-251, is designed to exploit a biological difference between cancerous and healthy cells. Many cancer cells contain elevated levels of reactive oxygen species (ROS) — chemically reactive molecules that can be used as a trigger.
When RK-251 enters a cancer cell with high ROS levels, the compound is designed to activate and release NBDHEX, a potent anticancer agent. NBDHEX targets proteins involved in cancer-cell survival and resistance to treatment.
In preclinical experiments, RK-251 showed strong activity against aggressive triple-negative breast cancer cells, while producing considerably less effect on healthy cells.
Researchers also tested the compound in zebrafish embryos. The experiments showed no obvious signs of toxicity, while fluorescence observed in the presence of ROS provided additional evidence that the drug was responding to its intended biological trigger.
The approach could potentially help address one of chemotherapy’s major limitations: damage to healthy cells alongside cancer cells, which can cause significant side effects.
However, researchers stress that RK-251 is still at the preclinical stage. The findings do not establish that the drug is safe or effective in humans. Further laboratory research, safety testing and properly designed clinical trials will be required before it could be considered for medical use.
If successful, the research could contribute to the development of cancer therapies that remain relatively inactive in healthy tissues but are selectively activated within tumour cells.
